<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767663</url>
  </required_header>
  <id_info>
    <org_study_id>P3</org_study_id>
    <nct_id>NCT00767663</nct_id>
  </id_info>
  <brief_title>Persantin Preceding Elective PCI</brief_title>
  <acronym>P3</acronym>
  <official_title>Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will investigate whether a short pretreatment (3-7 days) with&#xD;
      dipyridamole 200mg twice daily will protect patients against myocardial injury sustained&#xD;
      during an elective dotter operation of the coronary arteries (PCI).&#xD;
&#xD;
      The investigators hypothesize that dipyridamole can reduce myocardial injury sustained during&#xD;
      elective PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      In elective PCI (percutaneous coronary intervention) up to 40% of the patients show an&#xD;
      asymptomatic rise in myonecrosis marker troponin-I. This release of troponin-I has been found&#xD;
      to represent irreversible myocardial injury and has been related to an increased risk of&#xD;
      restenosis and even long-term mortality. Dipyridamole has been proven to induce protection&#xD;
      against ischemia reperfusion injury and to reduce risk of cardiovascular death or event in&#xD;
      secondary prevention after TIA or CVA.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test the hypothesis that dipyridamole improves tolerance to ischemia reperfusion injury in&#xD;
      patients undergoing elective PCI.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Double-blind placebo controlled intervention study&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients undergoing elective PCI&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      pretreatment with dipyridamole (Persantin Retard) 2dd 200mg or placebo.&#xD;
&#xD;
      Main study parameters:&#xD;
&#xD;
      Periprocedural troponin-I release measured 8 hours after PCI.&#xD;
&#xD;
      Bioequivalence study:&#xD;
&#xD;
      before the start of th clinical trial we will perform a bioequivalent study to test whether&#xD;
      our study medication (blinded by recapsuling) equals original dipyridamole capsules. 6&#xD;
      Healthy volunteers in a cross-over randomised design will take original dipyridamole 200 mg&#xD;
      SR and recapsuled dipyridamole 200mg SR (prepared by the department of pharmacy of the&#xD;
      RUNMC). Plasma dipyridamole concentration will be measured frequently and at baseline and 1&#xD;
      and 3 hours after administration of dipyridamole nucleoside transport inhibitions of&#xD;
      erythrocytes will be measured, to assess drug activity.&#xD;
&#xD;
      The clinical trial will only be initialized after conformation of bioequivalence of the study&#xD;
      medication to the original dipyridamole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac troponin-I</measure>
    <time_frame>before and 8 hours after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of pretreatment with dipyridamole 2x200mg on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9)</measure>
    <time_frame>3 days treatment minimal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PCI on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9)</measure>
    <time_frame>before and 8 hours after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Percutaneous Transluminal Coronary Angioplasty</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dipyridamole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyridamole</intervention_name>
    <description>dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment</description>
    <arm_group_label>1</arm_group_label>
    <other_name>persantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice daily, minimal three days pretreatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients accepted for elective single, native vessel (left anterior descending, right&#xD;
             coronary artery or ramus circumflexus (LAD, RCA or RCX)) PCI in the RUNMC&#xD;
&#xD;
          -  Troponin-I &lt; 0,20 mmol/L at screening&#xD;
&#xD;
          -  Signed Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable angina&#xD;
&#xD;
          -  recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion&#xD;
&#xD;
          -  3-Vessel disease as seen on coronary angiogram&#xD;
&#xD;
          -  Stenotic lesion in main stem as seen on coronary angiogram&#xD;
&#xD;
          -  CABG in medical history&#xD;
&#xD;
          -  asthma (recurrent episodes of dyspnoea and wheezing, or usage of prescribed inhalation&#xD;
             medication: i.e. corticosteroids or B2-agonists)&#xD;
&#xD;
          -  Treatment with insulin&#xD;
&#xD;
          -  Use of prescribed oral anticoagulants (coumarin derivates)&#xD;
&#xD;
          -  Use of oral corticosteroids&#xD;
&#xD;
          -  Use of sulfonylurea derivates (glibenclamide, tolbutamide, gliclazide, glimepiride)&#xD;
&#xD;
          -  Use of heparin or low molecular weight heparin&#xD;
&#xD;
          -  Use of metformin&#xD;
&#xD;
          -  Use of dipyridamole&#xD;
&#xD;
          -  Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAID's)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RUNMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Kleiman NS. Measuring troponin elevation after percutaneous coronary intervention: ready for prime time? J Am Coll Cardiol. 2006 Nov 7;48(9):1771-3. Epub 2006 Oct 17.</citation>
    <PMID>17084248</PMID>
  </reference>
  <reference>
    <citation>ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May 20;367(9523):1665-73. Erratum in: Lancet. 2007 Jan 27;369(9558):274.</citation>
    <PMID>16714187</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>G. Rongen</investigator_full_name>
    <investigator_title>G. Rongen MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

